// App-Quantinova.ai

: A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Researchers

Presenter

  • Sung-Soo Yoon

Principal Investigators

  • Dong-Yeop Shin

  • Je-Hwan Lee

  • Jun Ho Jang

  • June-Won Cheong

  • Ho-Jin Shin

  • Jeong-Ok Lee

  • Yunsuk Choi

  • Joseph Clarey

  • Jeejin Im

  • Suntae Kim

  • Ky-Youb Nam

  • Kyu-Tae Kim

  • June Han

  • Jeong Hyeok Yoon

  • Bao Nguyen

  • Li Li

  • Donald Small

Medical Centers

  • ICON caner centre, North Mackay, Australia

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)

  • Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, KOR

  • Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)

  • Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • Department of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • Australia

  • Republic of South Korea

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • gilteritinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved